Data as of Oct 21
| -0.08 / -0.71%|
The 8 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 15.50, with a high estimate of 18.00 and a low estimate of 11.00. The median estimate represents a +39.26% increase from the last price of 11.13.
The current consensus among 8 polled investment analysts is to Buy stock in Momenta Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.